文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

机器人立体定向体部放疗治疗前列腺癌的长期结果与PSA动力学:韩国多中心回顾性研究(韩国放射肿瘤学组研究15-01)

Long-term results and PSA kinetics after robotic SBRT for prostate cancer: multicenter retrospective study in Korea (Korean radiation oncology group study 15-01).
PubMed 文献 · Radiat Oncol · 2018-11-23

该多中心回顾性研究纳入88例局限性前列腺癌患者,采用射波刀SBRT(35-37.5 Gy/5次)治疗,中位随访63.8个月,5年生化失败无生存率为94.7%,2例发生晚期≥3级胃肠道毒性(2.2%);PSA达 nadir 时间与治疗结局显著相关,PSA下降模式因风险组而异。

要点

  • 5年生化失败无生存率为94.7%,晚期≥3级胃肠道毒性发生率为2.2%。
  • 中位PSA nadir为0.12 ng/mL,中位达nadir时间为44.8个月。
  • 24个月内达PSA nadir的患者BCFFS较差;PSA变化模式因风险组显著不同(p=0.011)。

核心结论

  • SBRT治疗局限性前列腺癌显示出良好疗效且毒性极小。
  • PSA达nadir时间与治疗结局显著相关。
  • PSA表现为初始快速下降、随随访延长下降减慢,且PSA变化模式因风险组而异。

研究设计与样本

  • 多中心回顾性研究,纳入三家学术医院收治的局限性前列腺癌患者。
  • 采用射波刀SBRT,剂量范围35至37.5 Gy,分5次照射。
  • 共88例患者,其中14例(15.9%)接受雄激素剥夺治疗(ADT)。
  • 生化失败采用Phoenix定义评估,毒性采用RTOG毒性标准评分。
  • PSA动力学仅在未接受ADT且无复发的患者中分析。

主要发现

  • 中位随访63.8个月,5年生化失败无生存率为94.7%。
  • 2例患者发生晚期≥3级胃肠道毒性(2.2%)。
  • 中位PSA nadir为0.12 ng/mL(范围0.00-2.62 ng/mL),中位达nadir时间为44.8个月(范围0.40-85.7个月)。
  • 24个月前达到nadir的患者BCFFS较其他患者差。
  • PSA下降速率在治疗后第一年最大,随时间逐渐减小;PSA变化模式因风险组显著不同(p=0.011),低、中、高危组的斜率分别为-0.139、-0.161和-0.253 ng/mL/月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To evaluate the treatment outcome and prostate-specific antigen (PSA) change after stereotactic body radiotherapy (SBRT) for localized prostate cancer. METHODS: Patients with localized prostate cancer treated with SBRT at three academic hospitals were enrolled. Treatment was delivered using Cyberknife with dose range from 35 to 37.5 Gy in 5 fractions. Biochemical failure (BCF) was assessed with Phoenix definition and toxicities were scored with Radiation Therapy Oncology Group (RTOG) toxicity criteria. The PSA kinetics were analyzed in patients who received no androgen deprivation therapy (ADT) and showed no recurrence. RESULTS: Of the total 88 patients, 14 patients (15.9%) received ADT. After median follow-up of 63.8 months, the 5-year BCF free survival (BCFFS) was 94.7%. Two patients experienced late grade ≥ 3 GI toxicities (2.2%). The median nadir PSA was 0.12 ng/mL (range, 0.00-2.62 ng/mL) and the median time to nadir was 44.8 months (range, 0.40-85.7 months). Patients who reached nadir before 24 months showed poorer BCFFS than the others. The rate of PSA decline was maximum in the first year after treatment and gradually decreased with time. The pattern of PSA change was significantly different according to the risk groups (p = 0.011) with the slope of - 0.139, - 0.161 and - 0.253 ng/mL/month in low-, intermediate- and high-risk groups, respectively. CONCLUSION: SBRT for localized prostate cancer showed favorable efficacy with minimal toxicities. The time to PSA nadir was significantly associated with treatment outcome. PSA revealed rapid initial decline and slower decrease with longer follow-up and the patterns of PSA changes were different according to the risk groups.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Park Y, Park HJ, Jang WI, et al. Long-term results and PSA kinetics after robotic SBRT for prostate cancer: multicenter retrospective study in Korea (Korean radiation oncology group study 15-01). Radiat Oncol. 2018. PMID: 30470253. doi:10.1186/s13014-018-1182-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。